LTRN

Lantern Pharma Inc. (LTRN) Economic Moat Analysis (2026)

Invetso Score: 1/10 — Weak · Last Updated: 2026-09-01

Overall Score

Scale Market Position

Micro-cap company with a market capitalization of $24.6M, indicating limited scale and likely weak competitive positioning.

No evidence in the fresh data of meaningful revenue base or operating scale; revenue per share remains 0.

Pricing Power Margins

TTM gross, operating, EBITDA, pretax, and net profit margins are all 0, showing no demonstrated pricing power or margin structure.

Negative profitability metrics across the board (ROA -2.17, ROE -4.56, ROIC -3.58) reinforce the absence of economic moat evidence.

Customer Stickiness Retention

No direct evidence of customer retention, recurring revenue, or switching costs in the fresh data.

The company’s zero revenue and zero margin profile provide no support for stickiness or durable customer relationships.

Intangible Assets Ip

Fresh metrics show no identifiable intangible asset base (intangibles to total assets = 0).

No news or financial evidence suggests proprietary IP, brand strength, or regulatory barriers.

Cost Advantage Efficiency

Operating efficiency remains poor, with negative operating cash flow and free cash flow yields (both negative).

The company does not show a cost advantage versus peers based on the current TTM metrics.

Network Effects Ecosystem

No evidence of network effects, platform dynamics, or ecosystem lock-in in the fresh data.

The latest metrics and news do not indicate any user growth or engagement flywheel.

Switching Costs Barriers

No evidence of switching costs or contractual lock-in is present in the current data.

The absence of revenue and customer metrics makes it difficult to infer any meaningful barriers to exit.

Financial Resilience

Liquidity is acceptable with a current ratio of 1.96 and cash ratio of 1.54, which provides some near-term cushion.

However, profitability and cash generation remain deeply negative, limiting the durability of any competitive position.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →